Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 15/20 | 0.39 |
| ▸ | JAK2 | O60674 | 13/20 | 0.39 |
| ▸ | JAK3 | P52333 | 11/20 | 0.39 |
| ▸ | TYK2 | P29597 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714981 | 0.64 | JAK1 (0.54) | JAK1JAK2JAK3 | |
| SCHEMBL1531578 | 0.61 | JAK1 (0.50) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL30941113 | 0.60 | CSF1R (0.72) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL4068076 | 0.59 | JAK3 (0.80) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL16793608 | 0.57 | BTK (0.54) | JAK1JAK2JAK3 | |
| SCHEMBL21372268 | 0.57 | JAK2 (0.68) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL17500879 | 0.56 | JAK2 (1.00) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL17951141 | 0.56 | JAK1 (0.69) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL26786653 | 0.56 | TTBK1 (0.57) | — | |
| SCHEMBL3584631 | 0.56 | MEN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | JAK1 3/4885JAK2 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.